summari report sale
underli ex-fx divestitur came
ahead estim
consensu respect growth led diabet
rtg restor therapi group post best quarter
rtg histori non-gaap ep ex-fx
came consensu estim ep
out-performance reflect strong top-lin growth
benefit fx tax top bottom-
line result strong oper margin expans
bp compar ex-fx basi bp guidanc
worth mention elect increas
spend consensu result strong
perform impact margin improv quarter
guidanc front rais fy sale guidanc
underli ex-fx vs previou guidanc
guid growth wed note mdt top-
line guidanc look conserv view particularli
soft prior year comp impact hurrican maria would
suspect deliv anoth strong quarter organ top-lin
growth model ex-fx mdt guidanc impli
roughli growth vs growth
manag attribut primarili tougher prior year compar
bottom-lin manag effect rais fy ep
ex-fx growth guidanc left
report ep guidanc unchang assum
ep
bigger pictur thought view execut well
recent quarter deliv organ ex-fx growth least
past three quarter believ see
anoth good quarter optic rel easi prior
year comp would like see continu execut progress
margin expans becom construct
name said still trade discount larg
cap med-tech peer group would surpris see
share trend higher come month especi given easi
comp
continu next page
compani data secur llc estim reuter
ep exclud amort reflect combin follow
acquisit cov
compani prioriti stock list
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
chang model decreas fy sale estim
organ ex-fx decreas fy non-gaap ep estim report
due primarili fx rais price target base cy
ep estim
 recap revenu underli ex-fx divestitur ahead estim
consensu worth note growth came well-abov mdt
guidanc repres sequenti acceler vs growth although
deceler stack basi report ep beat consensu
estim ep beat rel model primarili reflect higher revenu lower net
interest expens vs estim lower tax rate vs estim
partli off-set higher opex vs estim oper margin
repres bp improv compar ex-fx basi
four segment exceed street expect cardiac vascular group cvg
sale ex-fx beat consensu in-lin estim minim
invas therapi group mitg revenu grew underli beat consensu
forecast restor therapi group sale increas ex-fx ahead
consensu forecast diabet revenu rose ex-fx better
consensu estim
larg cap med-tech organ growth acceler behind easi comp
report tuesday morn aggreg growth rate larg cap
med-tech name see figur analysi indic world-wide organ ex-fx growth acceler
sequenti along mark fastest quarterli
growth rate sinc start analysi note growth benefit
crhf growth mix mdt crhf cardiac rhythm heart failur busi grew ex-fx
sequenti deceler ex-fx worth note crhf face toughest
prior year compar ex-fx high power remain soft implant
cardiovert defibril crt-d cardiac resynchron therapi defibril global sale
mid-singl digit low double-digit respect low power ww pacemak mid-single-
digit crt-p cardiac resynchron therapi pacemak grew small base
base competitor result estim world-wide ww market
declin ex-fx modestli ex-fx mdt af atrial fibril solut
grew high-teen roughli in-lin high-teen growth diagnost reveal linq
sale grew low-single-digit world-wide basi due competit trial regard htwr
estim lvad left ventricular assist devic contribut roughli cvg sale
particular strength us lvad revenu benefit level defer sale
quarter although understand benefit nearli complet
csh driven de tavr growth csh coronari structur heart revenu grew ex-fx
modest deceler growth csh growth larg driven high-teen
growth transcathet aortic valv replac tavr low double-digit growth de mdt us
tavr busi grew mid-teen behind continu uptak mdt evolut devic expans
us intermedi risk popul said ou tavr busi grew low ex-fx
primarili driven evolut estim ww tavr market grew ex-fx
somewhat ex-fx growth
de maintain doubl digit growth driven us strength mdt de drug-elut
stent revenu grew low double-digit ww modest deceler high-teen growth
de result reflect low growth us consist prior quarter growth
reflect continu strength resolut onyx de ou de sale growth low-
singl digit low-doubl digit prior quarter growth deceler like
reflect anniversari resolut onyx launch japan earli juli believ de share
us near all-tim high estim held share us ww de market
apv aortic peripher vascular overal growth stabl apv sale grew ex-fx
similar growth primarili reflect strong perform endoven dcb
drug coat balloon peripher mid-singl digit sale growth larg driven endoven
grew mid-teen vs high-singl digit growth attribut improv
growth strong demand venas closur system addit inpact admir dcb revenu
grew high-singl digit ww ou growth growth off-set low-
singl digit sale declin us howev note us dcb perform still better
expect follow recent reimburs chang note maintain global dcb share
leadership approv sfa superfici femor arteri indic estim held
share us dcb market follow bdx share philip aortic low-
singl digit growth larg driven growth thorac stent graft
global spine sale declin y/i ex-fx global spine sale y/i ex-fx
versu compani deliv similar growth bmp bone morphogenet protein
core spine categori diverg geograph perform deliv mid-
singl digit growth outsid us ou versu high-singl digit off-set
y/i declin us versu manag note call better proxi
spine busi perform rel competit global spine revenu combin spine
enabl technolog imag navig power system nerv monitor robot
combin growth y/i quarter improv
level indic spine procedur growth outpac market growth
fact compani core us spine busi ex-bmp combin spine enabl technolog grew
strong y/i quarter note spine enabl technolog report within rtg brain
divis neurosurgeri look ahead expect three factor drive compani spine growth
scale product launch core spine drive enabl technolog adopt increas
ou mix see good traction recent launch product includ elev solera
voyag fixat system prestig lp cervic disc addit mazorx robot continu
enabl growth spine interest note howev robot drive new surgeon
interest medtron offer navig look manag
believ integr platform imag navig robot power instrument
key drive spine growth strategi go forward
global spine market growth acceler cq global spine market ex-infus
y/i cq repres acceler y/i sequenti us
spine market ex-infus declin y/i cq repres modest improv
y/i meaning sequenti growth track better market ex-
infus y/i cq repres improv y/i sequenti
appear gain share intervent spine global us versu year ago
continu lose share core spine impli compani surgic synergi strategi gain
traction still earli day respect drive meaning implant pull
evalu orthoped strategi believ may opportun
compani disrupt scale busi orthoped alreadi establish surgic
synergi strategi spine evalu market respect device/impl and/or orthoped
bundl strategi note knee alreadi limit market releas hip offer
expect market near-futur manag note aggress
respect approach determin disrupt path forward
pain therapi continu rebound nice pain therapi sale grew y/i ex-fx ex-
fx reflect growth versu mid-teen spinal cord stimul
pain pump high-singl digit versu mid-singl digit intervent spine worth
note post three consecut quarter y/i growth turnaround
segment well underway result driven high growth us versu high teen
led intelli implant neurostimul evolv workflow manag note call
intelli drive custom demand given smaller system allow faster recharg
also comment see meaning tailwind us result opioid crisi
patient physician look altern solut overal estim medtron global
sale y/i ex-fx includ y/i us worth note
third quarter row sinc post posit us
growth encourag use fq result estim global market grew
y/i ex-fx slightli ahead level y/i us market grew y/i
also ahead level y/i
neurovascular growth remain strong mdt neurovascular revenu grew high-teen in-lin
growth compani attribut perform strength endovascular stroke
therapi includ flow divert stent retriev mdt strong neurovascular perform
direct consist competitor report neurotech growth
report neurovascular continu believ posit data stroke trial like
dawn defus past year help acceler growth overal stroke market
expand address patient popul recal dawn defus show
endovascular treatment stroke benefit patient beyond initi window onset
potenti extend treatment window hour includ mdt result estim
global neurovascular market grew consist growth
estim high-teen growth
mitg growth stabl mid-singl digit mitg sale total
compar ex-fx growth essenti in-lin growth within mitg growth led
surgic innov si growth compar ex-fx vs respiratori
gastrointestin renal sale grew compar ex-fx vs region growth
led emerg market compar ex-fx non-u develop market compar
us growth
surgic innov si solid si revenu grew essenti consist
growth reflect continu strong perform advanc advanc stapl
advanc surgic believ overal procedur volum fairli stabl
market new product help drive convers surgeri minim invas surgeri
therebi deliv share gain above-market growth advanc energi sale grew
low-doubl digit strong adopt recent launch enhanc ligasur vessel seal
instrument advanc stapl mid-singl digit growth larg reflect strong demand tri-
stapl reload signia power stapler comparison organ growth jnj advanc surgeri
busi consist growth jnj advanc energi growth
ou growth off-set us sale declin share loss robot reprocess
similarli endocutt continu see solid ou growth low-doubl digit seen
us sale declin due share loss robot
growth stabl sale rose ex-fx slightli growth
quarter primarili driven mid-singl digit growth gi led solid perform
therapeut diagnost respiratori renal solut rc sale rose low-singl digit
respiratori patient monitor grew low-singl digit due tough yr/yr comp sensor
despit high-singl digit growth capnographi ventil sale
surgic robot remain track major updat provid ceo omar ishrak note
call compani remain track robot assist surgeri platform compani
process receiv surgeon feedback good far accord recal
compani investor day june manag push robot launch timelin year
compani note time pre-clin test underway platform
would advanc clinic test full launch target
diabet sale y/i ex-fx global diabet sale y/i ex-fx
repres sequenti improv well turnaround
declin post fact diabet post best quarterli perform
decad sequenti growth led us versu non-u
develop market remain steadi emerg market deceler
versu reclassifi busi sub-seg advanc insulin
manag aim emerg technolog et aim deliv y/i growth led
sustain strong demand minim hybrid close loop system increas sensor
attach rate us strong demand minim initi uptak outsid
us worth note compani gain pump share quarter alon given
strong demand elsewher et deliv y/i growth led us launch guardian connect
mid-jun continu glucos monitor cgm market manag note launch
kick well surgar iq assist guardian connect make product
market offer person insight predict alert estim like gener
sale launch quarter
y/i ex-fx compar basi deceler growth
double-digit growth driven sever region within em- middl east africa southeast
asia china south asia eastern europ overal em revenu
quarter account revenu last quarter percent
estim large-cap med-tech median look ahead manag confid continu
gener double-digit growth em led diversif increas penetr therapi
within market
fy guidanc rais guidanc introduc earlier today rais fy sale
growth guidanc organ compar ex-fx basi expect fx
headwind fiscal impli report revenu rang
report mdt fy sale outlook busi follow cvg rtg
mitg expect grow around underli ex-fx divestitur diabet expect
grow low mid-teen stronger first half given prior year comp regard margin
continu expect achiev oper margin improv target ex-fx fiscal
increment benefit fx impli report basi bottom-
line manag effect rais guidanc fy non-gaap ep growth
compar ex-fx basi left report ep guidanc unchang
assum neutral fx impact vs previou benefit regard manag guid top-lin
growth organ compar ex-fx basi non-gaap ep expect
roughli fx headwind non-gaap ep
note organ growth adjust fx acquisitions/divestitur sell day weather meaning
note organ growth adjust fx acquisitions/divestitur sell day weather meaning
organ med-tech pf cfn average excl growth year stack med-tech pf cfn average excl medic technolog
price target
price target assum cy cash ep estim risk includ
weak key end market greater share loss model delay product launch
believ deliv averag organ growth due lull major new product launch
combin competitor headwind
found minneapolis-bas lead global medic technolog compani
focus provid therapi chronic diseas compani four primari busi cardiac
plc incom statementin million except per share datafisc year end etot net currenc y-i expensesresearch oper incomenet interest expens amort incom tax incom adj continu year-to-year incom year-to-year incom dilut share year-to-year compani report secur llc estim plc
vascular restor therapi minim invas therapi diabet revenu
